| Eligibility Criteria |
- Patients are eligible under ONE of the following criteria:
- Patients must have histologically confirmed rare cancer
- FOR PATIENTS ENROLLED IN EAY131 "NCI-MATCH" PRIOR TO EAY131 ADDENDUM 10 ONLY: Patients must have histologically confirmed rare cancer identified in Section 18.1 t that did not have a match to a molecularly-guided therapy on EAY131 "NCI-MATCH" protocol or who are off protocol treatment on EAY131
- Patients must be ≥ 18 years of age
- Patients must have a Zubrod Performance Status of 0-2
- No other prior malignancy is allowed except for the following:
- Adequately managed Stage I or II cancer from which the patient is currently in complete remission
- Any other cancer from which the patient has been disease free for one year
- Adequately managed Stage I or II follicular thyroid or prostate cancer is also eligible, wherein patient is not required to be in complete remission
- Patients may have received either prior anti-CTLA4 or other prior anti-PD-1/anti-PD-L1 therapy, not both, provided that it is completed ≥ 4 weeks prior to registration
- Patients with brain metastases or primary brain tumors must have completed treatment, surgery or radiation therapy ≥ 28 days prior to registration and have stable disease at time of registration. Metastatic brain parenchymal disease must have been treated and patient must be off steroids for 7 days prior to registration. Patients must have a CT or MRI scan of the brain to evaluate for CNS disease within 42 days prior to registration
- Patients must not currently be receiving any other investigational agents or any other systemic anti-cancer therapy (including radiation, excluding RANKL inhibitors and bisphosphonates)
Please contact Legacy Oncology Research for additional study inclusion/exclusion information. |
